Increlex (mecasermin) is a protein pharmaceutical. Mecasermin was first approved as Increlex on 2005-08-30. It has been approved in Europe to treat laron syndrome. The pharmaceutical is active against insulin-like growth factor I. In addition, it is known to target insulin-like growth factor 1 receptor.
|Drug Class||Growth factors: insulin-like growth factors|